<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068897</url>
  </required_header>
  <id_info>
    <org_study_id>2017-7566</org_study_id>
    <nct_id>NCT03068897</nct_id>
  </id_info>
  <brief_title>Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain</brief_title>
  <official_title>Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study, based in emergency departments, in which the investigators
      determine the utility of adding various skeletal muscle relaxants to standard therapy, which
      consists of ibuprofen and an educational session. Patients will be enrolled at the time of an
      emergency visit and followed for three months to determine outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Actual">October 11, 2018</completion_date>
  <primary_completion_date type="Actual">July 11, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Medications provided to patients are encapsulated. Medications vials are labelled with investigational stickers.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Roland Morris Disability Questionnaire (RMDQ)</measure>
    <time_frame>7 days</time_frame>
    <description>Improvement in RMDQ between baseline and 7 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scale</measure>
    <time_frame>48 hours, 7 days, 3 months</time_frame>
    <description>Severe, moderate, mild, or no low back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for medication for low back pain</measure>
    <time_frame>48 hours, 7 days, 3 months</time_frame>
    <description>Patients will be asked what medications they have used for low back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute score on Roland Morris Disability Questionnaire</measure>
    <time_frame>7 days, 3 months</time_frame>
    <description>This is a commonly used scale in low back pain research. It measures the impact of low back pain on one's life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Metaxalone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.
All participants receive a brief educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tizanidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.
All participants receive a brief educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.
All participants receive a brief educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.
All participants receive a brief educational intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaxalone</intervention_name>
    <description>Metaxalone 400-800mg</description>
    <arm_group_label>Metaxalone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tizanidine</intervention_name>
    <description>Tizanidine 2-4mg</description>
    <arm_group_label>Tizanidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>Baclofen 10-20mg</description>
    <arm_group_label>Baclofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 mg</intervention_name>
    <description>Ibuprofen</description>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_label>Metaxalone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tizanidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Educational intervention</intervention_name>
    <description>Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_label>Metaxalone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tizanidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present to ED primary for management of LBP, defined as pain originating between the
             lower border of the scapulae and the upper gluteal folds. Flank pain, that is pain
             originating from tissues lateral to the paraspinal muscles, will not be included.

          -  Musculoskeletal etiology of low back. Patients with non-musculoskeletal etiologies
             such as urinary tract infection, ovarian cysts, or influenza like illness will be
             excluded. The primary clinical diagnosis, at the conclusion of the ED visit, must be a
             diagnosis consistent with non-traumatic, non-radicular, musculoskeletal LBP.

          -  Patient is to be discharged home. Patients admitted to the hospital are more likely to
             be treated with parenteral medication and therefore are not appropriate for this
             study.

          -  Age 18-64 Enrollment will be limited to adults younger than 65 years because of the
             increased risk of adverse medication effects in the elderly.

          -  Non-radicular pain. Patients will be excluded if the pain radiates below the gluteal
             folds in a radicular pattern.

          -  Pain duration &lt;2 weeks (336 hours). Patients with more than two weeks of pain are at
             increased risk of poor pain and functional outcomes.(9)

          -  Prior to the acute attack of LBP, back pain cannot occur more frequently than once per
             month. Patients with more frequent back pain are at increased risk of poor pain and
             functional outcomes.(9)

          -  Non-traumatic LBP: no substantial and direct trauma to the back within the previous
             month

          -  Functionally impairing back pain: A baseline score of &gt; 5 on the Roland-Morris
             Disability Questionnaire

        Exclusion Criteria:

          -  Not available for follow-up

          -  Pregnant or breast-feeding

          -  Chronic pain syndrome defined as use of any analgesic medication on a daily or
             near-daily basis

          -  Allergic to or intolerant of investigational medications

          -  Contra-indications to non-steroidal anti-inflammatory drugs: 1) history of
             hypersensitivity to NSAIDs or aspirin 2) active or history of peptic ulcer disease,
             chronic dyspepsia, or active or history of gastrointestinal bleed 3) Severe heart
             failure (NYHA 2 or worse) 4) hypertension (JNC7 stage 2 or worse) 5) Chronic kidney
             disease 3 or worse 6) Current use of anti-coagulants 7) Hepatitis 8) Alcoholism

          -  Contra-indications to muscle relaxants: 1) Concurrent use of centrally acting opioids;
             2) Renal impairment; 3) Liver abnormality including cirrhosis or elevated enzymes 4)
             Use of any of the following medications: fluvoxamine, fluoroquinolones, amiodarone,
             mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine,
             oral contraceptive pills
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>per patient</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Associate professor of emergency medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Tizanidine</mesh_term>
    <mesh_term>Baclofen</mesh_term>
    <mesh_term>Metaxalone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be available</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>November 7, 2019</submitted>
    <returned>November 25, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

